Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

Published: 09 September 2020
on channel: AJMCtv MJH

518

Prior to this year’s virtual American Society of Clinical Oncology conference held in May, Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, spoke with The American Journal of Managed Care® on the results of the CITYSCAPE trial, which she presented at the conference. The phase 2 results show that tiragolumab plus atezolizumab may be a chemotherapy-free treatment option for patients with metastatic nonsmall cell lung cancer.

Watch video Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC online, duration hours minute second in high quality that is uploaded to the channel AJMCtv MJH 09 September 2020. Share the link to the video on social media so that your subscribers and friends will also watch this video. This video clip has been viewed 518 times and liked it 1 visitors.

7,155